



## Clinical Trial Opportunities

Updated October 13, 2020

For more information on our studies call our research line at **416-386-9606** or email **research@memorydisorders.ca**

### Studies for Alzheimer's disease Prevention

#### **AHEAD 3-45 Study (Enrolment to begin in October 2020)**

The purpose of this study is to determine whether an investigational drug (BAN2401) vs. placebo can prevent symptomatic Alzheimer's disease in individuals at risk based on age, genetic risk, or amyloid biomarkers. Study participants are enrolled in one of two AHEAD trials, A3 or A45, based on whether they have intermediate or elevated levels of amyloid in the brain:

**Who:** 55-80 years old, cognitively well.

**Duration:** Treatment for 216 weeks (4 years).

### Mild Cognitive Impairment (MCI)

#### **AgeneBio HOPE4MCI**

A study evaluating the efficacy and safety of AGB101 (low-dose levetiracetam, 220 mg, extended release tablet) vs. placebo on slowing progression of mild cognitive impairment due to Alzheimer's disease.

**Who:** Individuals 55 to 85 years old with Mild Cognitive Impairment.

**Duration:** Treatment for up to 78 weeks.

### Mild Cognitive Impairment (MCI) and mild Alzheimer's disease

#### **Eisai CLARITY**

To evaluate the efficacy of BAN2401 vs. placebo in slowing disease progression in individuals with early Alzheimer's disease.

**Who:** Individuals 50 to 90 years old with Mild Cognitive Impairment or mild dementia due to AD.

**Duration:** Double blind treatment for 18 months, Open label treatment for up to 2 years.

#### **Eli Lilly TRAILBLAZER-ALZ 2**

A study evaluating the efficacy and safety of donanemab vs. placebo in individuals with early symptomatic Alzheimer's disease.

**Who:** Individuals 60 to 85 years old with Mild Cognitive Impairment or mild dementia due to Alzheimer's disease.

**Duration:** Treatment for up to 76 weeks.

### **Anavex 2-73 (Enrollment to begin August 2020)**

A study evaluating the efficacy and safety of ANAVEX2-73 vs. placebo in individuals with symptomatic Early Alzheimer's disease.

**Who:** Individuals 60 to 85 years old with Mild Cognitive Impairment or Mild dementia due to AD.

**Duration:** Treatment for up to 48 weeks.

### **Janssen (Enrollment to begin September 2020)**

A study evaluating the efficacy and safety of JNJ-63733657 vs. placebo in individuals with early Alzheimer's disease.

**Who:** Individuals 55 to 80 years old with Mild Cognitive Impairment or mild dementia due to Alzheimer's disease.

**Duration:** Treatment for up to 4.5 years.

## **Studies for Those with Mild to Moderate Alzheimer's disease**

### **Green Memory (Enrollment to begin November 2020)**

A study evaluating the efficacy and safety of sodium oligomannate (GV-971) in treatment of mild to moderate Alzheimer's disease.

**Who:** Individuals 50 to 85 years old with mild to moderate dementia due to Alzheimer's disease.

**Duration:** Treatment for up to 52 weeks. Participants who completes the 52 weeks of treatment may continue into a 26 week Open Label Extension (if eligible).

## **Studies for Those with Moderate to Severe Alzheimer's disease**

### **Vielight (Enrollment to begin August 2020)**

A study evaluating the feasibility, safety, and efficacy of the Vielight Neuro RX Gamma for the treatment of moderate to severe Alzheimer's disease.

**Who:** Individuals 50+ with moderate to severe Alzheimer's disease.

**Duration:** Treatment for up to 12 weeks.

## **Non-Interventional Studies**

### **RetiSpec**

RetiSpec is a medical imaging company developing a tool for the early detection of Alzheimer's disease biomarkers in the eye.

**Who:** Individuals 50-90 who are at risk for or those who have pre-clinical Alzheimer's disease or who meet the clinical criteria for MCI.

**Duration:** A one hour session involving photos of the eye using standard eye exam equipment.

For more information on our studies call our research line at **416-386-9606** or email **[research@memorydisorders.ca](mailto:research@memorydisorders.ca)**